Phase 3 study of EDG-5506
Latest Information Update: 14 Apr 2025
At a glance
- Drugs Sevasemten (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
Most Recent Events
- 02 Apr 2025 According to a Edgewise Therapeutics media release, the company has announced the pricing of its 9,935,419 shares and anticipates gross proceeds from the offering to be approximately $200 million. The company intends to use the net proceeds from this offering to support many research activities along with the advancement of this trial.
- 08 Aug 2024 According to a Edgewise Therapeutics media release, this trial is planned to be initiated in the first half of 2025.
- 26 Oct 2023 According to a Edgewise Therapeutics media release, this trial is expected to start in the second half of 2024.